NextCure is a clinical-stage biopharmaceutical company focused on discovering and developing immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Co.'s main product candidate NC318, is an immunomedicine targeting an immunomodulatory receptor called Siglec-15. Co.'s second product candidate, NC410, is an immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1. The NXTC stock yearly return is shown above.
The yearly return on the NXTC stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2020 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the NXTC annual return calculation with any dividends reinvested as applicable (on ex-dates).
|